Meyka Pro banner
Bausch Health Companies Inc.

Bausch Health Companies Inc. Fundamental Analysis (NYSE: BHC)

BHCNYSE
HealthcareDrug Manufacturers - Specialty & Generic
$6.29
$0.05(0.88%)
U.S. Market is Open · 13:58

Bausch Health Companies Inc. Fundamental Analysis (NYSE: BHC)

Bausch Health Companies Inc. (NYSE: BHC) shows moderate financial fundamentals with a PE ratio of -2.11, profit margin of -10.12%, and ROE of 88.77%. The company generates $10.8B in annual revenue with moderate year-over-year growth of 8.53%.

Key Strengths

ROE88.77%
Operating Margin25.44%
Cash Position78.49%
PEG Ratio0.00

Areas of Concern

No major concerns flagged.
We analyze BHC's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 171.0/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
171.0/100

We analyze BHC's fundamental strength across five key dimensions:

Efficiency Score

Weak

BHC struggles to generate sufficient returns from assets.

ROA > 10%
-4.43%

Valuation Score

Excellent

BHC trades at attractive valuation levels.

PE < 25
-2.11
PEG Ratio < 2
0.00

Growth Score

Moderate

BHC shows steady but slowing expansion.

Revenue Growth > 5%
8.53%
EPS Growth > 10%
4.31%

Financial Health Score

Excellent

BHC maintains a strong and stable balance sheet.

Debt/Equity < 1
-11.73
Current Ratio > 1
1.44

Profitability Score

Moderate

BHC maintains healthy but balanced margins.

ROE > 15%
88.77%
Net Margin ≥ 15%
-10.12%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BHC Expensive or Cheap?

P/E Ratio

BHC trades at -2.11 times earnings. This suggests potential undervaluation.

-2.11

PEG Ratio

When adjusting for growth, BHC's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Bausch Health Companies Inc. at -1.32 times its book value. This may indicate undervaluation.

-1.32

EV/EBITDA

Enterprise value stands at -8.12 times EBITDA. This is generally considered low.

-8.12

How Well Does BHC Make Money?

Net Profit Margin

For every $100 in sales, Bausch Health Companies Inc. keeps $-10.12 as profit after all expenses.

-10.12%

Operating Margin

Core operations generate 25.44 in profit for every $100 in revenue, before interest and taxes.

25.44%

ROE

Management delivers $88.77 in profit for every $100 of shareholder equity.

88.77%

ROA

Bausch Health Companies Inc. generates $-4.43 in profit for every $100 in assets, demonstrating efficient asset deployment.

-4.43%

Following the Money - Real Cash Generation

Operating Cash Flow

Bausch Health Companies Inc. produces operating cash flow of $1.80B, showing steady but balanced cash generation.

$1.80B

Free Cash Flow

Bausch Health Companies Inc. generates strong free cash flow of $1.39B, providing ample flexibility for dividends, buybacks, or growth.

$1.39B

FCF Per Share

Each share generates $3.71 in free cash annually.

$3.71

FCF Yield

BHC converts 60.10% of its market value into free cash.

60.10%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.11

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.002

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.32

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.21

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-11.73

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.44

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.89

vs 25 benchmark

ROA

Return on assets percentage

-0.04

vs 25 benchmark

ROCE

Return on capital employed

0.14

vs 25 benchmark

How BHC Stacks Against Its Sector Peers

MetricBHC ValueSector AveragePerformance
P/E Ratio-2.1131.56 Better (Cheaper)
ROE88.77%441.00% Weak
Net Margin-10.12%18300.00% Weak
Debt/Equity-11.730.73 Strong (Low Leverage)
Current Ratio1.445.63 Neutral
ROA-4.43%1512.00% Weak

BHC outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Bausch Health Companies Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

24.55%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

127.35%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

20.61%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ